Standout Papers

The diagnosis and management of nonalcoholic fat... 2008 2026 2014 2020 4.9k
  1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2017)
    Naga Chalasani, Zobair M. Younossi et al. Hepatology
  2. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012)
    Naga Chalasani, Zobair M. Younossi et al. Hepatology
  3. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis (2010)
    Arun J. Sanyal, Naga Chalasani et al. New England Journal of Medicine
  4. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (2012)
    Naga Chalasani, Zobair M. Younossi et al. Gastroenterology
  5. Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States (2008)
    Naga Chalasani, Robert J. Fontana et al. Gastroenterology
  6. ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury (2014)
    Naga Chalasani, Paul H. Hayashi et al. The American Journal of Gastroenterology
  7. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease (2021)
    Arun J. Sanyal, Mark L. Van Natta et al. New England Journal of Medicine
  8. Endpoints and clinical trial design for nonalcoholic steatohepatitis (2011)
    Arun J. Sanyal, Elizabeth M. Brunt et al. Hepatology
  9. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study (2018)
    Eduardo Vilar‐Gómez, Luis Calzadilla Bertot et al. Gastroenterology
  10. Drug-induced liver injury (2019)
    Raúl J. Andrade, Naga Chalasani et al. Nature Reviews Disease Primers
  11. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease (2018)
    Mohammad Shadab Siddiqui, Raj Vuppalanchi et al. Clinical Gastroenterology and Hepatology
  12. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers (2017)
    Eduardo Vilar‐Gómez, Naga Chalasani Journal of Hepatology
  13. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012)
    Naga Chalasani, Zobair M. Younossi et al. The American Journal of Gastroenterology
  14. Serum Ferritin Is An Independent Predictor of Histologic Severity and Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2011)
    Kris V. Kowdley, Patricia Belt et al. Hepatology
  15. Nonalcoholic Fatty Liver Disease and the Heart (2019)
    Eric Stahl, Devinder S. Dhindsa et al. Journal of the American College of Cardiology
  16. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease (2019)
    David E. Kleiner, Elizabeth M. Brunt et al. JAMA Network Open
  17. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial (2021)
    Samer Gawrieh, Mazen Noureddin et al. Hepatology
  18. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury (2021)
    Naga Chalasani, Haripriya Maddur et al. The American Journal of Gastroenterology
  19. High‐quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population (2021)
    Eduardo Vilar‐Gómez, Lauren Nephew et al. Hepatology
  20. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH (2025)
    Mazen Noureddin, Mary E. Rinella et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 266 standout
Sub-graph 1 of 17

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis
2024 Standout
216 intermediate papers

Works of Naga Chalasani being referenced

Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
2018 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
and 61 more

Author Peers

Author Last Decade Papers Cites
Naga Chalasani 25932 13934 4979 9759 485 35.8k
Christopher P. Day 22363 9924 2804 9677 183 30.3k
Geoffrey C. Farrell 19440 9801 2103 6780 213 25.5k
Elizabeth M. Brunt 38092 17176 1493 15206 268 48.9k
Brent A. Neuschwander‐Tetri 24212 9883 1025 10995 186 29.7k
Anna Mae Diehl 34550 15918 1499 14288 405 50.2k
Arthur J. McCullough 27432 11779 828 11652 292 34.4k
Rohit Loomba 38376 19761 739 13696 687 47.8k
Giulio Marchesini 24065 10549 735 12125 461 34.6k
Keith D. Lindor 24788 22219 937 5525 431 35.9k
Kris V. Kowdley 19511 14089 782 4983 446 28.4k

All Works

Loading papers...

Rankless by CCL
2026